When to consider an inborn error of immunity: clues for physicians Authors: Meera Thangarajah, Lucinda J. Berglund Published: 2026 ABSTRACT AbstractThe term inborn errors of immunity (IEIs) refers to the rapidly expanding group of genetic disorders causing dysregulation of the immune system. With improved genetic testing in recent years, the number of defined IEIs and their range of phenotypic presentations has grown vastly, with more than 550 IEIs now described. IEIs cause diverse clinical manifestations, including infection, autoimmunity, lymphoproliferation, allergy and malignancy, with initial manifestations often appearing long before the diagnosis of an IEI is made. Furthermore, IEIs are increasingly diagnosed in adulthood, and a family history of disease is not always apparent. Physicians in all specialties are likely to encounter patients with IEIs, often before a formal diagnosis of an IEI is made or immunology consultation sought. Early diagnosis of an IEI improves patient outcomes through access to specialist immunology services and the potential for more specific, targeted treatment options. All physicians, therefore, need an understanding of IEIs and presenting manifestations in order to identify these patients early. This review outlines common clinical presentations of IEIs in adulthood across different specialties, including guidelines regarding when an underlying IEI should be considered. Abbreviations acquired errors of immunity autoimmune regulator anti‐neutrophil cytoplasmic antibody activated PI3K delta syndrome autoimmune polyendocrinopathy‐candidiasis‐ectodermal dystrophy autoimmune polyendocrine syndrome 1 coeliac disease chronic granulomatous disease central nervous system chronic obstructive pulmonary disease coronavirus disease of 2019 C‐reactive protein cytotoxic T‐lymphocyte associated protein 4 common variable immunodeficiency deficiency of adenosine deaminase 2 diffuse large B‐cell lymphoma dedicator of cytokinesis 8 Epstein–Barr virus gluten‐free diet gastrointestinal granulomatous‐lymphocytic interstitial lung disease granulocyte‐macrophage colony‐stimulating factor haploinsufficiency A20 human herpes virus 8 hyper IgE syndrome haemophagocytic lymphohistiocytosis human papillomavirus inflammatory bowel disease inborn error of immunity interstitial lung disease immune dysregulation, polyendocrinopathy, enteropathy, X‐linked interleukin‐1 receptor‐associated kinase 4 lupus nephritis mevalonate kinase deficiency Mendelian susceptibility to mycobacterial disease natural killer primary immunodeficiency disorder systemic lupus erythematosus stimulator of interferon genes type 1 diabetes Wiskott‐Aldrich syndrome Background Inborn errors of immunity (IEIs) are an expanding group of disorders in which identified genetic variants cause immune dysfunction. More than 550 IEIs have now been described, affecting all aspects of the immune system, and the number continues to grow with advances in genetic testing. 1 Historically, many IEIs were described as ‘primary immunodeficiency disorders’ (PIDs) which primarily presented in childhood with recurrent infections; however, it is now understood that immunodeficiency is only one component of immune dysfunction and that the spectrum of IEIs encompasses other types of immune dysregulation, including autoimmunity, autoinflammation, lymphoproliferation, allergy and malignancy. Currently, 20% of IEIs will not present with infection, 2 , 3 and more than 50% will be diagnosed at greater than 25 years of age. 4 , 5 The expansion of adult diagnoses can be attributed to several factors, including increased awareness of IEIs and their diverse manifestations, advances in genetic testing allowing genetic diagnoses for new presentations and the revisiting of prior diagnoses with new information, variable phenotypes and the delayed onset of some IEIs which only cause symptoms in adulthood. In adults, an IEI‐like phenotype may also arise without a germline pathogenic variant. These acquired errors of immunity (AEI) include phenocopies due to acquired somatic variants and autoantibodies targeting cytokines. 6 In routine practice, the distinction between IEI and AEI is not always clear at presentation; therefore, the term IEI/AEI is used where appropriate. Although IEI/AEIs can present at any age, diagnosis is often significantly delayed. 4 Early recognition improves outcomes by enabling targeted immune evaluation, preventing irreversible organ damage such as bronchiectasis thereby reducing morbidity and mortality, facilitating surveillance for other manifestations of IEI/AEI including malignancy and encouraging family planning and screening of family members. 7 As precision therapies for individual IEIs emerge, such as leniolisib for activated PI3K delta syndrome (APDS), 8 which was recently approved for use in Australia by the Therapeutic Goods Administration, timely identification of patients with IEI/AEI becomes increasingly important. Consequently, all physicians need a general understanding of IEIs/AEIs; however, a detailed knowledge of hundreds of new specific diagnoses is not necessary. This review provides adult physicians with high‐yield clinical patterns or ‘clues’ that should prompt consideration of IEI/AEI and referral for immunology assessment (Fig. 1). Key considerations and clues for physicians regarding IEI/AEI. Infectious diseases In adults, infection‐related presentations remain one of the most common entry points to the recognition of an underlying IEI/AEI (Fig. 2). However, infection alone is rarely the most informative clue; rather the clinical context, including family history of IEI/AEI (even when affected relatives display different phenotypes), recurrent or severe infections, consanguinity, recurrent miscarriage or infant death, autoimmune disease or early/atypical malignancy, provides the greatest diagnostic value. 9 Many patients, however, will not have a known family history of IEI, so the absence of a family history does not exclude this diagnosis. 2 Both within an individual and within a family, more than one sign of immunodysregulation or multisystem involvement alongside infection is particularly suggestive of IEI/AEI, including enteropathy, lymphoproliferation or autoimmune cytopenias, allergy, cancer, granulomatous disease, chronic lung disease and autoinflammation. 10 Infectious disease clues. Recurrent, severe or unusual infections are important signs of a possible IEI/AEI, particularly when infections are disproportionate to exposures or comorbidities, recur despite appropriate antimicrobial therapy, require prolonged or intravenous treatment, or involve opportunistic organisms. Notably, human immunodeficiency virus infection remains an important cause of secondary immunodeficiency and should be excluded before pursuing evaluation for IEI/AEI. 11 Specific patterns of infection include recurrent and/or severe bacterial infections such as pneumonia and deep skin or organ abscesses, recurrent infections of a limited type, such as mucocutaneous fungal, herpesvirus or mycobacterial infections, and unusual infections such as severe or recurrent warts or molluscum contagiosum. 5 , 9 , 12 , 13 Infections of specific organs are addressed in the relevant sections below. An abnormal inflammatory response may also be indicative of an underlying IEI/AEI. ‘Cold’ abscesses with minimal erythema or pus formation are characteristic of conditions such as hyper‐IgE syndrome and chronic granulomatous disease. Separately, clinically severe infection with disproportionately low serum acute‐phase reactants is a recognised feature of hyper‐IgE syndrome and interleukin‐1 receptor‐associated kinase 4 (IRAK4) deficiency. 14 Recurrent febrile inflammatory episodes without an identifiable infectious source should prompt consideration of periodic fever syndromes and other autoinflammatory syndromes. In adults, AEIs increasingly account for IEI‐like infectious phenotypes and should be considered alongside germline disorders. Neutralising anti‐cytokine autoantibodies can produce highly specific infection patterns that mirror monogenic IEIs. 15 In particular, anti‐interferon‐γ antibodies cause disseminated non‐tuberculous mycobacterial and non‐typhoidal salmonella infections that phenocopy Mendelian susceptibility to mycobacterial disease (MSMD). 16 Similarly, anti‐GM‐CSF antibodies predispose to cryptococcal meningitis and Nocardia infection, while anti‐type I interferon antibodies are strongly associated with life‐threatening viral infections, including severe COVID‐19 pneumonia in previously healthy adults. 17 , 18 Recognition of these patterned infections is critical, as diagnosis relies on targeted immunological testing rather than genetic analysis. Respiratory Respiratory involvement is the most frequent and often earliest clinical clue to an underlying IEI/AEI (Fig. 3). Recurrent or severe sinopulmonary infections including chronic sinusitis, otitis media and pneumonia are often a first warning sign of IEI/AEI in both adults and children, with up to 70%–80% of common variable immunodeficiency (CVID) patients experiencing at least one episode of pneumonia prior to diagnosis. 19 , 20 Pneumonia occurring in two or more consecutive years, or two or more bronchial infections with cough and purulent sputum per year, are considered recurrent. 21 Even if total serum immunoglobulins are normal, a specific antibody deficiency, causing an impaired antibody response to polysaccharide‐coated organisms such as Streptococcus pneumoniae and Haemophilus influenzae, could be present. Respiratory clues. Structural lung disease in IEI/AEI may be the result of recurrent respiratory tract infections or a sequela of the underlying immune defect. A history of complications related to infections in young patients, in particular bronchiectasis, bronchial wall thickening, abscess, empyema or pneumatocele, is a warning sign for underlying IEI/AEI. 19 Certain pulmonary manifestations are suggestive of specific IEIs: pneumatoceles in autosomal‐dominant hyper‐IgE syndrome, bronchiectasis in antibody deficiency syndromes, severe bronchiolitis in severe combined immunodeficiency and invasive fungal pulmonary infections in phagocyte disorders. 21 In patients with primary antibody deficiency syndromes, bronchiectasis tends to involve the middle or lower lobes with a diffuse, bilateral distribution. Radiologically, tubular or cylindrical forms predominate, while varicose and cystic types are less common. 22 In patients with chronic obstructive pulmonary disease (COPD) experiencing two or more moderate to severe acute exacerbations per year despite maximal medical therapy for COPD, an underlying antibody deficiency (primary or secondary to corticosteroids) should be considered. 23 Similarly, severe or steroid‐resistant asthma, especially when accompanied by recurrent infections, hypogammaglobulinaemia or systemic autoimmunity, may represent an underlying IEI/AEI. 19 , 24 Interstitial lung disease (ILD) can complicate IEI/AEIs, arising either from immune dysregulation or secondary to infection. 25 Granulomatous‐lymphocytic ILD (GLILD), often associated with CVID, is characterised by non‐caseating granulomas, interstitial lymphocytic infiltration and lymphoid hyperplasia. 19 Radiological hallmarks of GLILD include diffuse interstitial infiltrates on plain X‐ray, multifocal pulmonary consolidation, pulmonary nodules, interlobular septal thickening, ground‐glass opacities and reticular abnormalities on high‐resolution computed tomography. GLILD often occurs with splenomegaly, hilar and mediastinal lymphadenopathy. 19 In distinction from pulmonary sarcoidosis, GLILD is associated with a normal serum angiotensin‐converting enzyme and lung nodules that are often over 1 cm in size in a basal distribution, in contrast to the smaller, apical and peri‐lymphatic‐distributed nodules in sarcoidosis. 26 Stimulator of interferon genes (STING)‐associated vasculopathy classically presents in infancy; however, it may occasionally present to adult respiratory physicians with ILD or progressive pulmonary fibrosis driven by type 1 interferon signalling, typically associated with acral cutaneous manifestations. 27 Other histological patterns reported in IEIs/AEIs include organising pneumonia, non‐specific and usual interstitial pneumonia. 26 Gastroenterology Gastrointestinal (GI) manifestations are present in up to 50% of patients with IEIs/AEIs and can mimic classic GI diseases such as inflammatory bowel disease (IBD) and coeliac disease (CD) (Fig. 4). 28 , 29 , 30 , 31 Atypical GI symptoms, atypical histology, failure to respond to conventional treatment or need for multiple immunosuppressive agents, or severe course of disease indicated by malabsorption requiring parenteral nutrition, could suggest an underlying IEI/AEI. 28 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 Gastroenterology clues. Acute or chronic infectious diarrhoea is the cause of GI disease in 20%–60% of patients with CVID, encompassing pathogens such as Giardia lamblia, Campylobacter jejuni, Salmonella spp, Cryptosporidium, Cytomegalovirus and enteroviruses including norovirus. 28 , 41 In patients with antibody deficiency, Giardia lamblia is the most frequent symptomatic GI infection, presenting with bloating, cramping and watery diarrhoea. 28 , 42 Non‐infectious enteropathy due to immune dysregulation is a significant clinical entity in IEI/AEI. IEI/AEI‐associated enteropathy can present in adults with no prior or known family history of IEI/AEI and in the absence of other typical manifestations such as recurrent infections. While specific histological diagnostic criteria are yet to be defined, studies of small bowel biopsies in patients with IEI/AEI‐related enteropathy demonstrate a combination of heterogenous findings including villous atrophy, increased intraepithelial lymphocytosis, increased epithelial apoptotic bodies, nodular lymphoid hyperplasia and paucity of mucosal plasma cells. 30 , 43 , 44 , 45 Coeliac‐like histology with lack of response to gluten‐free diet (GFD) should prompt immunological evaluation rather than prolonged escalation of ‘refractory coeliac disease’ pathways. 46 These patients may have subtle histological differences including a lower level of intraepithelial lymphocytosis, absent plasma cell infiltration, acute duodenitis with strong neutrophil infiltration and follicular lymphoid hyperplasia compared to true CD; however, these are variable and inconsistent, and the main clue to an IEI is the lack of response to a GFD. 44 , 47 , 48 Patients with selective IgA deficiency have a 10‐ to 20‐fold increased risk of true CD (typically responsive to GFD) 49 , 50 ; however, serum IgA antibodies to endomysium, gliadin and tissue transglutaminase (tTG) may be negative. In these patients, IgG antibodies to deamidated gliadin peptides and tTG are highly specific. 51 Histopathological changes in IEI/AEI‐related enteropathy may resemble IBD‐like colitis with discontinuous inflammation, mucosal ulceration, transmural inflammation, cryptitis and crypt abscess formation. 45 , 52 , 53 CVID‐associated enteropathy may also mimic lymphocytic colitis, collagenous colitis and colitis associated with graft‐versus‐host disease. 48 , 54 These features, in combination with refractory disease or poor response to usual IBD treatment, presence of other atypical histopathological features such as plasma cell paucity or other clinical features of immunodysregulation, should direct the clinician towards immunological evaluation. Conditions such as chronic granulomatous disease (CGD) and mevalonate kinase deficiency (MKD), which may present in or persist into adulthood, can also demonstrate an IBD‐like phenotype and should be considered in severe or atypical presentations. In CGD, colitis is often granulomatous with prominent perianal disease, and concomitant infection is characterised by abscess formation or invasive fungal infection. In MKD, GI inflammation is accompanied by recurrent febrile inflammatory episodes and poor response to conventional IBD therapy. 28 Liver disease can also occur in IEI/AEIs. Patients with CVID may develop chronic cholestatic liver derangement, often associated with nodular regenerative hyperplasia on liver biopsy, along with autoimmune cytopenias, polyclonal lymphoproliferation and granulomatous disease. A subset of patients display interface hepatitis similar to autoimmune hepatitis but lacking typical autoantibodies. 55 Acute and chronic liver inflammation associated with CVID often shows mild non‐specific portal and lobular inflammation with absent plasma cells and no or mild portal fibrosis. 56 Haematology Cytopenias and/or lymphoproliferation are frequent initial manifestations of IEI/AEI (Fig. 5). 57 The risk of an individual with an IEI/AEI developing an autoimmune cytopenia is at least 120 times higher than the general population, and the cumulative incidence of autoimmune manifestations rises linearly throughout life up to at least the eighth decade. 58 The combination of autoimmune haemolytic anaemia and immune thrombocytopenia (Evans syndrome) is particularly suggestive of an IEI/AEI, with up to 65% of patients in a paediatric population carrying pathogenic or probable pathogenic variants. 59 Failure of a cytopenia to respond to first‐line therapy is another clue to consider an IEI/AEI. 57 Haematology clues. Broadly, different haematological presentations within the same family can also indicate an underlying IEI/AEI, even if those presentations appear mild. For example, a mother presenting with autoimmune cytopenia and her child with non‐malignant lymphoproliferation raises suspicion for an IEI/AEI. 60 Non‐malignant lymphoproliferation, including lymphadenopathy, splenomegaly, hepatomegaly and/or lymphoid infiltration, is another frequent presenting manifestation of IEI/AEI. 60 , 61 Atypical histological features suggesting an IEI/AEI include granulomas, CD8+ T‐cell infiltrates, polyclonal B‐cell lymphoproliferation, massive follicular hyperplasia and germinal centre disruption. 61 , 62 , 63 Autoimmune lymphoproliferative syndrome should be explicitly considered in patients with chronic non‐malignant lymphadenopathy and/or splenomegaly and autoimmune cytopenias, a diagnosis supported by elevated double‐negative T cells in peripheral blood. 64 The relative risk of lymphoma in patients with IEI/AEI is eight‐ to 10‐fold that of the age‐matched population, particularly B‐cell non‐Hodgkin lymphomas of extranodal onset and diffuse large B‐cell lymphoma (DLBCL); however, other types are also found. 65 The average age at onset of lymphoma is in adolescence or early adulthood; however, this varies significantly between different IEI/AEIs. 65 , 66 In CVID, the average age at lymphoma onset is in the 40s and 50s, 65 , 67 and lymphoma can be the initial presenting manifestation of CVID in adults. 68 , 69 In APDS, the average age of lymphoma occurrence is 18–19. 66 , 70 Adult haematologists, therefore, need to be vigilant for the possibility of an IEI underlying lymphoma presentations. Other clues include lymphoma presenting with an atypical site of disease (e.g. extranodal) and persistent hypogammaglobulinaemia after lymphoma treatment. 65 International classification systems such as the fifth edition of the WHO Classification of Haematopoietic and Lymphoid tissues (WHO‐HAEM5) now recognise underlying immunodeficiency and immunodysregulation as a distinct subgroup, and this includes IEI/AEI. 71 Early data suggest that lymphomas in IEI/AEI might be genetically distinct, with more frequent mutations in particular genes such as BRCA2, NCOR1, FAS and BRWD3 than non‐IEI DLBCLs. 66 Distinct mutational fingerprints in specific IEIs, such as APDS, may also be observed. 66 , 72 Identification of such genetic patterns would then facilitate the diagnosis of an underlying IEI/AEI. Haemophagocytic lymphohistiocytosis (HLH) or HLH‐like disease can occur in patients with IEI/AEI. Pathogenic variants affecting natural killer (NK) cell and cytotoxic T lymphocyte function underlie adult‐onset HLH in 14% of cases. 73 Many other IEI/AEIs also predispose to infection‐triggered HLH, including CGD. 74 Adult patients presenting with HLH in isolation or associated with colitis, granulomatous disease or history of recurrent infection should receive prompt treatment according to severity. The smaller proportion of aberrant NK/T cell IEI‐associated HLH can be investigated with NK cell functional testing or flow cytometry‐based assays for cytotoxic defects and genetic testing for HLH‐associated variants; however, treatment should not be delayed while awaiting these results. Oncology Children and adults with IEI/AEI have an increased risk of cancers compared to the general population (Fig. 6). 75 Cancer risk varies with the underlying genetic variant; however, overall, the estimated lifetime risk of developing cancer in a child with IEI is estimated at 4%–25% and cancer is the second most common cause of death after infection in children and adults with IEI. 75 , 76 , 77 The latency between IEI/AEI diagnosis and cancer diagnosis also varies between different IEIs/AEIs; however, cancer can be the initial manifestation, particular in the context of delayed IEI/AEI diagnosis or milder phenotype. 75 , 78 Oncology clues. The most common neoplasm associated with IEI/AEI is lymphoma, particularly extranodal non‐Hodgkin lymphoma, as described earlier. 78 However, solid organ tumours can also occur, including gastric adenocarcinoma, thymoma and rarely breast cancer, neuroblastoma and medulloblastoma. 75 IEI/AEIs causing DNA repair defects, such as ataxia‐telangiectasia, confer particular cancer risk in patients, including haematological malignancies but also epithelial malignancies and solid organ tumours. 75 Heterozygous carriers of these variants may also have an increased cancer risk. 79 In paediatric populations, the type of solid organ tumours associated with IEIs/AEIs are often distinct from those seen in children without IEIs/AEIs, such as papillary thyroid carcinoma. 78 A childhood history of an unusual tumour type for a given age is therefore another clue to consider an IEI/AEI in an adult. Antibody deficiency such as CVID is associated with an increased risk of lymphoma and gastric cancer (up to 47‐fold in one study), and premalignant gastric changes have been identified in 34% of CVID patients. 80 , 81 Gastric cancer associated with CVID tends to occur at a younger age than in the general population, with a mean age of gastric cancer diagnosis in CVID in the fifth decade, compared to the seventh decade in the general population. 82 , 83 Histologically, CVID‐associated gastric cancer may have distinct features. It is usually a moderate to poorly differentiated intestinal type adenocarcinoma with a high number of intratumoural lymphocytes, arising on a background of severe gastric atrophy with intestinal metaplasia, pan‐gastric distribution, plasma cell paucity, lymphoid nodular aggregates and apoptotic activity. 82 , 84 Some IEIs/AEIs predispose to chronic viral infection, including oncoviruses such as Epstein–Barr virus (EBV), human herpesvirus 8 (HHV8) and human papillomavirus (HPV). Viral associated neoplasms can occur, including EBV‐related lymphomas and soft tissue tumours, HHV8‐related Kaposi sarcoma, and HPV wart‐related anogenital carcinoma. 85 More than 20% of carcinomas in IEI/AEI are associated with chronic infection. 86 Diagnosis of a viral‐associated neoplasm warrants consideration of an underlying IEI/AEI unless other risk factors are apparent. Endocrinology The endocrine system is frequently involved in IEIs/AEIs (Fig. 7). In one cohort, 21% of patients with IEI had at least one endocrine disorder, with thyroid disease being the most prevalent. 1 , 87 Autoimmune disease affecting endocrine organs is the most common cause of dysfunction; however, interpretation of standard investigations may be challenging as patients with antibody deficiency may fail to generate disease‐specific autoantibodies, while those receiving immunoglobulin replacement may have detectable donor‐derived autoantibodies, leading to false‐negative or false‐positive results. 88 As such, if clinical suspicion remains high, alternate investigations should be pursued. Endocrinology clues. Physicians should also be aware of multiple coexisting endocrinopathies caused by IEIs/AEIs. Autoimmune polyendocrine syndrome 1 (APS‐1), also called APECED (autoimmune polyendocrinopathy‐candidiasis‐ectodermal dystrophy), caused by pathogenic variants in the autoimmune regulator (AIRE) gene, is a heterogeneous disease causing a range of endocrinopathies. The classic triad of mucocutaneous hypoparathyroidism and hypoadrenalism only presents simultaneously in 20% of patients, with 70% developing all three manifestations by the age of 25. 89 Some manifestations may not appear until over the age of 40, leading to significant diagnostic delays. 90 Other less common endocrinopathies in APS‐1 include type 1 diabetes (T1D), hypothyroidism and hypogonadism. Partial DiGeorge syndrome represents a milder and often under‐recognised form of 22q11.2 deletion‐associated immune dysregulation that may present for the first time in adolescence or beyond. 91 Unlike complete DiGeorge syndrome, immune deficiency may be subtle or variable, and patients primarily present with endocrine or neurocognitive and psychiatric features. A review of late‐onset DiGeorge syndrome, defined as diagnosis after age 13 and with the majority of identified patients aged 18 or over, found that 53% of cases reported symptomatic hypocalcaemia secondary to hypoparathyroidism as the most common first presentation. 91 Hypothyroidism and obesity also occur frequently (44% and 38% of patients respectively in one study) in late‐onset DiGeorge syndrome, reinforcing the importance of screening for IEI/AEI in patients presenting with multiple coexisting endocrinopathies. 92 IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X‐linked) is caused by pathogenic variants in FOXP3 affecting regulatory T‐cell function. 93 While it typically presents in infancy with a triad of severe enteropathy, T1D and eczema, rare delayed, mild or atypical single organ presentations have been reported up to age 12 or potentially older. 94 , 95 , 96 T1D is the most common endocrinopathy in IPEX, but thyroiditis, hypoadrenalism and growth hormone deficiency can also occur. 94 Neurology Neurological disease occurs in a range of IEIs/AEIs, although initial manifestations of IEI/AEI are less frequently neurological. Unexplained neurological symptoms, especially in the context of other suggestive features, such as lymphoproliferation or recurrent infection, warrant consideration of an IEI/AEI (Fig. 8). Individuals with IEIs/AEIs are at increased risk of infection, such as viral encephalitis, as well as infection with unusual organisms and vaccination‐related infections, which can present neurologically. Brain biopsy with metagenomic analysis has shown potential in enabling the detection of atypical cerebral infections, which has occasionally led to the diagnosis of an underlying IEI. 97 Neurology clues. Vasculopathy is a feature of some IEI/AEIs, and neurological complications of cerebral vasculopathy can be the initial presenting manifestation. 98 Deficiency of adenosine deaminase 2 (DADA2) causes early‐onset strokes and peripheral vasculopathy resembling polyarteritis nodosa, as well as fevers, livedo racemosa and sometimes cytopenias and immunodeficiency. 99 , 100 Vasculopathy is present in 75%, affecting skin, brain, GI tract or renal vessels, and neurological involvement in over 50%. 101 , 102 Ischaemic strokes are frequently small lacunar infarcts in the brainstem or deep grey matter and can be recurrent in the absence of systemic inflammation. 103 Wide phenotypic variability means that although the majority present as children or young adults, patients can present at any age or remain asymptomatic throughout life and can have severe multiorgan disease or more limited involvement. 101 Heterozygous individuals can also present with strokes. 102 Strokes and/or peripheral neuropathy in the presence of fever, a raised C‐reactive protein (CRP), skin changes (such as livedo racemosa, erythema nodosum or urticaria) or a recurrent or chronic course are clues to consider an IEI such as DADA2. 102 Other IEI/AEIs causing vasculopathy which can present with neurological involvement include STING‐associated vasculopathy with onset in infancy and haploinsufficiency A20 (HA20) due to TNFAIP3 variants. 98 HA20 resembles Behcet disease, causing oral and genital ulcers, arthralgias, skin involvement such as erythema nodosum and abdominal symptoms. Features that may suggest HA20 rather than Behcet disease include childhood onset, prominent fever, lack of the classical HLA‐B51 association and inconsistent response to colchicine. 98 , 104 Non‐infective central nervous system (CNS) inflammation has also been demonstrated in IEIs/AEIs associated with immunodysregulation, such as CTLA4 haploinsufficiency. Neurological manifestations are broad, including optic neuritis, autoimmune encephalitis and CNS infiltration from lymphoproliferation, and can present in adulthood. 105 , 106 In this context, a personal or family history of other features of immunodysregulation would be a clue for the presence of an IEI/AEI. Renal Renal disease is rarely an isolated presenting feature of IEI/AEI in adults; however, it may provide important diagnostic clues when it occurs alongside other features of systemic immune dysregulation, or in atypical, treatment‐refractory autoimmune renal disease or absence of expected autoantibodies based on suggestive histology. Monogenic lupus pathways should be considered in early‐onset or familial severe lupus nephritis. Dermatology Cutaneous manifestations are reported in 40%–70% of IEIs/AEIs, often presenting early in the disease course and preceding diagnosis by years (Fig. 9). 107 , 108 Certain dermatological findings are highly specific for an underlying IEI/AEI. For example, telangiectasiae in a patient with neuro‐oculomotor features point to ataxia‐telangiectasia, granulomatous plaques or ‘cold’ cutaneous abscesses are characteristic of CGD, and the triad of chronic mucocutaneous candidiasis, urticarial rash and ectodermal hypoplasia in APS‐1 (discussed previously). 109 , 110 Early recognition of this skin eruption can facilitate the diagnosis years before other aspects of the clinical triad arise. 111 Eczematous dermatitis is seen in many IEIs/AEIs and is especially characteristic of hyper‐IgE syndromes and Wiskott‐Aldrich syndrome (WAS). It may present as typical eczema with a tendency to become secondarily infected, widespread or severe and unresponsive to conventional treatment. 108 , 112 , 113 In WAS, areas of eczematous dermatitis are often accompanied by petechiae and ecchymoses due to thrombocytopenia. 113 Dermatology clues. Recurrent, severe or atypical cutaneous infections are warning signs of an underlying IEI/AEI. For example, recurrent folliculitis and ‘cold’ abscess formation with localisation to the scalp, face and neck suggest hyper‐IgE syndrome, recurrent staphylococcal cutaneous infections CGD, and absence of pus formation in painful, spreading lesions of leukocyte adhesion deficiency. 108 Extensive, recalcitrant or disseminated viral infections (such as molluscum contagiosum, herpes simplex virus and HPV) suggest T‐cell/NK cell dysfunction, notably DOCK8 deficiency, which combines severe atopy with recurrent cutaneous viral infections. 114 Furthermore, chronic or recurrent mucocutaneous candidiasis should trigger evaluation for STAT1 gain‐of‐function mutations and APS‐1. 115 , 116 Autoimmune skin disease can occur in IEI/AEIs. For example, vitiligo and alopecia areata are strongly associated with APS‐1, while lupus‐like rashes, vasculitis and granulomatous dermatitis are described in CVID and complement deficiencies. 108 Conclusion IEIs/AEIs cause diverse clinical presentations across a wide range of specialties and are most effectively recognised through attention to clinical context rather than isolated findings. Features such as disease severity, treatment resistance, atypical age of onset, discordant serological and histological patterns, suggestive family history or consanguinity and the presence of multisystem involvement should prompt consideration of underlying immune dysregulation. Awareness of these manifestations enables early immunology referral, diagnosis and access to emerging targeted therapies.